Sufentanil pharmacokinetics in a full-term neonate treated with extracorporeal membrane oxygenation: a case report

Abstract

Introduction:

Sufentanil is a potent analgesic drug used for pain management. A few studies describe the pharmacokinetics of sufentanil in neonates; however, no pharmacokinetic data about sufentanil during extracorporeal membrane oxygenation have been published yet.

Case report:

A 1-day-old neonate with moderate hypoxic–ischemic encephalopathy received veno-arterial extracorporeal membrane oxygenation support for refractory respiratory and circulatory failure. Sufentanil plasma concentrations were determined during both extracorporeal membrane oxygenation (n = 14) and non–extracorporeal membrane oxygenation (n = 17) period. Based on these measurements, individual sufentanil pharmacokinetic parameters were calculated.

Discussion:

We observed increased sufentanil volume of distribution (11.6 vs 5.6 L/kg) and decreased sufentanil clearance (0.535 vs 0.746 L/h/kg) in extracorporeal membrane oxygenation period. The increment of volume of distribution was attributed to ECMO influence, while difference in clearance was probably due to drug interaction.

Conclusions:

This is the first description of sufentanil pharmacokinetics in neonate treated with extracorporeal membrane oxygenation. We observed considerably larger volume of distribution during extracorporeal membrane oxygenation period in comparison with non–extracorporeal membrane oxygenation period.

Keywords

sufentanil extracorporeal membrane oxygenation neonate pharmacokinetics

Get full access to this article

View all access options for this article.

References

Davis

Cook

Stiller

et al . Pharmacodynamics and pharmacokinetics of high-dose sufentanil in infants and children undergoing cardiac surgery. Anesth Analg 1987; 66: 203–208.

Davis

Cook

DR.

Clinical pharmacokinetics of the newer intravenous anaesthetic agents. Clin Pharmacokinet 1986; 11: 18–35.

Davis

Stiller

Cook

et al . Pharmacokinetics of sufentanil in adolescent patients with chronic renal failure. Anesth Analg 1988; 67: 268–271.

Greeley

De Bruijn

Davis

DP.

Sufentanil pharmacokinetics in pediatric cardiovascular patients. Anesth Analg 1987; 66: 1067–1072.

Lundeberg

Roelofse

JA.

Aspects of pharmacokinetics and pharmacodynamics of sufentanil in pediatric practice. Paediatr Anaesth 2011; 21: 274–279.

Anand

Hickey

PR.

Halothane-morphine compared with high-dose sufentanil for anesthesia and postoperative analgesia in neonatal cardiac surgery. N Engl J Med 1992; 326: 1–9.

Guay

Gaudreault

Tang

et al . Pharmacokinetics of sufentanil in normal children. Can J Anaesth 1992; 39: 14–20.

Seguin

Erenberg

Leff

RD.

Safety and efficacy of sufentanil therapy in the ventilated infant. Neonatal netw 1994; 13: 37–40.

Bartkowska-Sniatkowska

Bienert

Wiczling

et al . Pharmacokinetics of sufentanil during long-term infusion in critically ill pediatric patients. J Clin Pharmacol 2016; 56: 109–115.

10.

Wildschut

Van Saet

Pokorna

et al . The impact of extracorporeal life support and hypothermia on drug disposition in critically ill infants and children. Pediatr Clin North Am 2012; 59: 1183–1204.

11.

Raffaeli

Allegaert

Koch

et al . In vitro adsorption of analgosedative drugs in new extracorporeal membrane oxygenation circuits. Pediatr Crit Care Med 2018; 19: e251–e258.

12.

Azzopardi

Strohm

Edwards

et al . Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med 2009; 361: 1349–1358.

13.

Taketomo

Hodding

Kraus

DM.

Pediatric & neonatal dosage handbook: with international trade names index: a universal resource for clinicians treating pediatric and neonatal patients. 20th ed. Hudson, OH: Lexicomp Inc., 2013.

14.

Harris

Ramelet

Van Dijk

et al . Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: an ESPNIC position statement for healthcare professionals. Intensive Care Med 2016; 42: 972–986.

15.

Flint

Bahmany

Van Der Nagel

BCH

et al . Simultaneous quantification of fentanyl, sufentanil, cefazolin, doxapram and keto-doxapram in plasma using liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2018; 32: e4290.

16.

Sima

Netikova

Slanar

Pregnane xenobiotic receptors and their effect on drug elimination from the organism. Prague Med Rep 2013; 114: 205–213.

17.

Dossing

Pilsgaard

Rasmussen

et al . Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol 1983; 25: 215–222.

18.

Magnusson

Karlsson

Sandstrom

A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat. Pharm Res 2006; 23: 521–532.

19.

Pokorná

Posch

Šima

et al . Severity of asphyxia is a covariate of phenobarbital clearance in newborns undergoing hypothermia. J Matern Fetal Neonatal Med 2019; 32: 2302–2309.

20.

Pokorna

Wildschut

Vobruba

et al . The impact of hypothermia on the pharmacokinetics of drugs used in neonates and young infants. Curr Pharm Des 2015; 21: 5705–5724.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.07 MB